Nasdaq
$3.94▼ 1.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $92.4MShares out 23.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 10.14Pre-market26.10.14 21:308-KKey event#●●●#●●●
Coya Therapeutics, Inc.
Coya Therapeutics plans to initiate an open-label extension (OLE) for its Phase 2/3 ALSTARS trial of COYA 302 in ALS starting in November 2026. Consequently, the Phase 2 clinical trial for frontotemporal dementia (FTD), previously expected in the second half of 2026, has been rescheduled to 2027. The company maintains its cash runway guidance, with existing resources expected to fund operations through the second half of 2027.…more
$3.94-1.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5Pre-market26.10.05 21:308-KKey event
Coya Therapeutics, Inc.
Coya Therapeutics has completed the enrollment of 120 patients for its Phase 2/3 ALSTARS trial evaluating the ALS treatment candidate COYA 302. Topline data from the double-blind treatment phase of the study are expected to be released in early Q2 2027.…more
$3.94-1.25%vs prev closeView filingShare - 9.15Pre-market26.09.15 21:158-KKey event
Coya Therapeutics, Inc.
Coya Therapeutics has enrolled the 100th patient in its ongoing Phase 2/3 ALSTARS trial for COYA 302, a treatment for ALS. The company expects to complete the full enrollment of 120 participants shortly and plans to report topline data in early Q2 2027.…more
$3.94-1.25%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Pre-market26.10.14 21:03#●●●#●●●
Coya Therapeutics to Initiate Open-Label Extension for ALS Trial
Coya Therapeutics plans to start an open-label extension for its Phase 2/3 ALSTARS trial evaluating COYA 302 for ALS treatment. While this allows for longer-term data collection, the company has deferred the start of its FTD clinical trial to 2027.…more
$3.94-1.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.5Pre-market26.10.05 21:03
●●●●●●●● ●●●●● ●●●●●●
Coya Therapeutics has successfully enrolled all 120 planned participants for its Phase 2/3 ALSTARS trial of COYA 302 for ALS. Topline data from the study is expected to be released in early Q2 2027.…more
$3.94-1.25%vs prev closeShareBenzinga - 9.15Pre-market26.09.15 21:03
●●●●●●●● ●●●●● ●●●●●●
Coya Therapeutics has reached a milestone by enrolling the 100th participant in its Phase 2/3 trial for COYA 302, a treatment for ALS. Topline data from the study is currently anticipated to be released in early Q2 2027.…more
$3.94-1.25%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report